why novartis� landmark cancer drug approval is great news for bluebird .
the uk�s initial plan had been challenged in court by the .-related side effects. its manufacturer, eli lilly, plans to submit a new drug application to the fda in the second half of 2018. .
"there is an issue that needs to be addressed in terms of the narrative the health trust tried to present and mislead the inquest and cover up what actually happened. .